These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33611389)

  • 1. The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?
    Dal Pino B; Bigazzi F; Sbrana F; Sampietro T
    Eur J Prev Cardiol; 2021 Dec; 28(15):e16-e18. PubMed ID: 33611389
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTERIM guidelines for the diagnosis and management of familial hypercholesterolaemia.
    Sullivan DR; Hamilton-Craig I; van Bockxmeer F; Watts GF;
    Heart Lung Circ; 2012 Mar; 21(3):159-62. PubMed ID: 22364837
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
    Mol MJ; Erkelens DW; Gevers Leuven JA; Schouten JA; Stalenhoef AF
    Atherosclerosis; 1988 Feb; 69(2-3):131-7. PubMed ID: 3279966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor.
    Thiery J; Armstrong VW; Schleef J; Creutzfeldt C; Creutzfeldt W; Seidel D
    Klin Wochenschr; 1988 May; 66(10):462-3. PubMed ID: 2969433
    [No Abstract]   [Full Text] [Related]  

  • 7. Guidelines for the identification and management of patients with familial hypercholesterolaemia (FH): are we coming to a consensus?
    Humphries SE
    Atheroscler Suppl; 2011 Oct; 12(2):217-20. PubMed ID: 22230092
    [No Abstract]   [Full Text] [Related]  

  • 8. Familial hypercholesterolaemia.
    Nair DR; Sharifi M; Al-Rasadi K
    Curr Opin Cardiol; 2014 Jul; 29(4):381-8. PubMed ID: 24870549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic principles of food related problems--familial hypercholesterolaemia].
    Floré M; Robberecht N; Hermans H
    J Pharm Belg; 2012 Mar; (1):18-21. PubMed ID: 22536679
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of PCSK9 in familial hypercholesterolaemia.
    Sijbrands EJ
    Lancet; 2012 Jul; 380(9836):6-7. PubMed ID: 22633823
    [No Abstract]   [Full Text] [Related]  

  • 11. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis.
    Hemphill LC
    J Clin Lipidol; 2010; 4(5):346-9. PubMed ID: 21122676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.
    Langslet G
    Eur Heart J; 2016 May; 37(17):1357-9. PubMed ID: 27026748
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to Dr. Gerald M Reaven: good news for patients with familial hypercholesterolaemia: statins are not diabetogenic in this disease.
    Vuorio A; Strandberg TE; Schneider WJ; Kovanen PT
    J Intern Med; 2016 Oct; 280(4):419-20. PubMed ID: 27451964
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipoprotein Apheresis and PCSK9-Inhibitors. Impact on Atherogenic Lipoproteins and Anti-Inflammatory Mediators in Familial Hypercholesterolaemia.
    Stefanutti C; Zenti MG
    Curr Pharm Des; 2018; 24(31):3634-3637. PubMed ID: 30360706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial hypercholesterolaemia in Australia: new insights and developments.
    Hamilton-Craig IR; Watts GF
    Med J Aust; 2013 Feb; 198(2):72-3. PubMed ID: 23373481
    [No Abstract]   [Full Text] [Related]  

  • 16. [Management in familial hypercholesterolaemia in children and adolescents. Position of the Lipid Expert Forum].
    Myśliwiec M; Walczak M; Małecka-Tendera E; Dobrzańska A; Cybulska B; Filipiak KJ; Mazur A; Jarosz-Chobot P; Szadkowska A; Rynkiewicz A; Chybicka A; Socha P; Brandt A; Kubalska J; Bautembach-Minkowska J; Limon J; Zdrojewski T; Limon J; Banach M;
    Kardiol Pol; 2013; 71(10):1099-105. PubMed ID: 24197602
    [No Abstract]   [Full Text] [Related]  

  • 17. Familial hypercholesterolaemia: different perspectives.
    Jones JL; Lakasing E; Archontakis S
    Nurs Stand; 2009 Aug 19-25; 23(50):35-8. PubMed ID: 19736707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prediction of the therapeutic response to cholesterol lowering drugs in an 11-year-old boy with homozygous familial hypercholesterolaemia.
    Bakker HD; Bruin T; Schaap MC; Lansberg PJ; Kastelein JJ
    J Inherit Metab Dis; 1991; 14(3):389-92. PubMed ID: 1663193
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipoprotein (a) in familial hypercholesterolaemia.
    Durrington PN; Bashir B; Bhatnagar D; Soran H
    Curr Opin Lipidol; 2022 Aug; 33(4):257-263. PubMed ID: 35942820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a).
    Vuorio A; Watts GF; Kovanen PT
    Eur Heart J; 2017 Dec; 38(48):3555-3559. PubMed ID: 29029165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.